Fosun Pharma: The holding subsidiary Fosun Pharmaceutical Industry has signed a licensing agreement with Sitala.

Fosun Pharma announced that its subsidiary Fosun Pharma Industry has signed a licensing agreement with Sitala, granting Sitala the right to develop, manufacture, and commercialize FXS6837 and its related products worldwide. According to the agreement, Sitala will pay a first payment of up to $190 million and milestone payments for development and commercialization.